Perrigo grapples with European OTC problem

16 May 2016 - Deborah Wilkes

Archived

Perrigo recorded an impairment charge of US$467 million related to its Branded Consumer Healthcare business – formerly the Omega Pharma European OTC business – in the first quarter of 2016. As a result, Perrigo reported a net loss of US$335 million in the three months.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: